Answers are grounded in this paper and cite their sources.
Objective: To evaluate the pharmacodynamics of aqueous humor (AH) free VEGF concentrations after treatment with the Port Delivery Platform with ranibizumab (PDS) in patients with neovascular age-related macular degeneration (nAMD). Design: Pharmacokinetic and pharmacodynamic analyses from the phase III Archway (NCT03677934) and phase II Ladder (NCT02510794) trials. Participants: Patients with treatment-responsive nAMD. Methods: In Archway, patients received PDS 100 mg/mL with refills every 24 weeks (Q24W) or intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W) for 96 weeks. In Ladder, patients received PDS 10, 40, or 100 mg/mL with refills based on protocol-defined criteria or intravitreal ranibizumab 0.5 mg Q4W. Aqueous humor samples were collected throughout the trials (PDS arms only in Ladder) in a subset of patients. Main Outcome Measures: Aqueous humor ranibizumab and free VEGF concentrations. Results: pg/mL, there was a negative correlation between AH free VEGF and AH ranibizumab concentration. There were no correlations between AH free VEGF concentrations and clinical outcomes in either arm, including change from baseline in best-corrected visual acuity and central subfield thickness at week 96. Conclusions: These findings demonstrate that PDS 100 mg/mL Q24W suppresses AH free VEGF throughout the entire 24-week refill-exchange interval and to an extent similar to that at 4 weeks after intravitreal ranibizumab. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
No takes yet. Share an insight, caveat, or question.
Maass et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: